Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/PRS.0000000000007936 | DOI Listing |
Publication Analysis
Top Keywords
reply dipeptidyl
4
dipeptidyl peptidase-4
4
peptidase-4 inhibitor
4
inhibitor reduces
4
reduces risk
4
risk developing
4
developing hypertrophic
4
hypertrophic scars
4
scars keloids
4
keloids median
4
Similar Publications
Reply to Firneisz: "Rebound increase in circulating dipeptidyl peptidase-4 (DPP4) enzyme activity after acute Covid-19".
Proc Natl Acad Sci U S A
January 2023
State Key Laboratory for Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Sciences, Xiamen University, Fujian 361102, China.
Reply: Dipeptidyl Peptidase-4 Inhibitor Reduces the Risk of Developing Hypertrophic Scars and Keloids following Median Sternotomy in Diabetic Patients: A Nationwide Retrospective Cohort Study Using the National Database of Health Insurance Claims of Japan.
Plast Reconstr Surg
June 2021
Department of Plastic and Reconstructive Surgery, General Informatics Division, Tokyo Medical University, Tokyo, Japan.
Reply to Picod : Alteration of the Renin-Angiotensin-Aldosterone System in Shock: Role of the Dipeptidyl Peptidase 3.
Am J Respir Crit Care Med
February 2021
The University of Melbourne Melbourne, Victoria, Australia.
SGLT-2 inhibitors for people with type 2 diabetes - Authors' reply.
Lancet
August 2019
TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA 02115, USA. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!